TICKERNERD
Menu
AZRAZRHealthcare · Biotechnology

AZR Stock Forecast: Adial Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$5.05
+36.12% on the day

The 4 Wall Street analysts covering Adial Pharmaceuticals, Inc. hold a median 12-month price target of $8 — +58.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$9.7M
Ticker Nerd rank
21/ 100
Median analyst target
$8.00
Analysts covering
4
Revenue$0.0
Operating income−$52.0M
Net income−$52.0M
Free cash flow−$6.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+22.9%
1M
+25.0%
YTD
−8.2%
1Y
−46.8%
From 52W high
−46.8%
From 52W low
+271.3%
$1.36
$9.50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AZR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Adial Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
21/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Accruals
69
Revisions
43
Momentum
40
Volatility
28
Growth
27
Value
26
Quality
14
Issuance
2

Size (89): Smaller than most of the companies we track.

Issuance (2): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AZR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AZR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26AZRHigh $11.00Median $8.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
3 Buy1 Hold0 Sell
Low $6.00Median $8.00High $11.00

The green dot is the last close — the median target sits +58.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Aug 2026Alliance Global PartnersInitiatesBuy$11
15 June 2026LUCID CAPITAL MARKETSInitiatesBuy$6.00
15 June 2026LUCID CAPITAL MARKETSInitiatesBuy—
30 Sept 2025Maxim GroupUpgradeBuy—
14 Nov 2024Rodman & RenshawInitiatesBuy—
12 July 2023Brookline CapitalReiteratesBuy—
11 July 2023Brookline CapitalReiteratesBuy$6.00
17 Aug 2022Maxim GroupDowngradeHold—
13 Oct 2021Brookline CapitalInitiatesBuy—
29 June 2021Litchfield HillsInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

AZR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AZR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Adial Pharmaceuticals, Inc. returned −46.8% against +13.6% for the S&P 500, dividends included.

AZR vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26AZRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AZR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Adial Pharmaceuticals, Inc. (AZR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
—
Price / book
−0.5×

Cheaper than 94% of US stocks

EV / EBITDA
−1.7×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−2011.6%

Higher than 1% of US stocks

Return on assets
−40.0%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Adial Pharmaceuticals, Inc. (AZR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Adial Pharmaceuticals, Inc. has a market value of $9.7M and an enterprise value of $19.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$57.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$11.1M.

  • Shares outstanding: 2.6M.

  • Trailing P/E: 0.0×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Adial Pharmaceuticals, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

AZR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AZRAdial Pharmaceuticals, Inc.$9.7M21
CNSYCerenome, Inc.$13.2M16
DAREDaré Bioscience, Inc.$13.2M30
KTTAPasithea Therapeutics Corp.$13.1M16
TCRXTScan Therapeutics, Inc.$13.0M55
PBMPsyence Biomedical Ltd.$13.0M4
BOLTBolt Biotherapeutics, Inc.$12.6M87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Adial Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AZR news & analysis

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

GlobeNewsWire · 28 Oct 2026neutral

Adial Pharmaceuticals announced it has changed its corporate name to Azora Therapeutics, with its common stock expected to begin trading on Nasdaq under AZR on October 29, 2026. The company also announced a new executive team and said it expects to initiate a Phase 1 trial of AT177 in the first half of 2027.

Why it matters — ADIL watchers should note the company’s rebranding and ticker change, along with its stated development plans for AT177, an oral, colon-targeted AhR agonist for ulcerative colitis.

Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer

GlobeNewsWire · 26 Oct 2026neutral

Adial Pharmaceuticals said Celia Economides, its current Executive Vice President of Finance, is expected to become CFO after the reconvened 2026 Annual Meeting, if certain proposals are approved. She is expected to lead finance and capital strategy as the company transitions to Azora Therapeutics and advances AT177 toward the clinic.

Why it matters — The planned leadership change could affect ADIL’s finance organization and capital strategy during its transition and clinical-development plans.

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

GlobeNewsWire · 16 Oct 2026positive

Adial Pharmaceuticals appointed David Rubenstein, M.D., Ph.D., as chief scientist to advance its colon-targeted AhR agonist AT177 for ulcerative colitis. Rubenstein previously led the development of tapinarof, described as the first FDA-approved AhR agonist, through approval and commercialization.

Why it matters — The appointment brings experience with an approved AhR agonist to the development of Adial’s AT177 program.

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 30 Sept 2026neutral

Adial Pharmaceuticals announced that its Compensation Committee granted a new employee stock option to purchase 155,446 shares of common stock as an inducement for the person becoming an employee of the Company. The grant was made under Nasdaq Listing Rule 5635(c)(4).

Why it matters — ADIL watchers would care because this inducement grant signals new hiring activity and potential share dilution through the option to purchase 155,446 shares.

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 25 Aug 2026neutral

Adial Pharmaceuticals announced that its Compensation Committee granted a new employee stock option to purchase 307,814 shares of common stock as an inducement for the person becoming an employee, under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The inducement grant signals new hiring activity and potential equity dilution for existing shareholders, which ADIL watchers may monitor.

FAQ

Frequently asked questions about AZR stock

What is the AZR stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Adial Pharmaceuticals, Inc. have a median 12-month price target of $8, with estimates ranging from $6 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AZR stock a buy right now?

Of the 4 analysts covering Adial Pharmaceuticals, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adial Pharmaceuticals, Inc. 21 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AZR?

As at 28 Oct 2026, Adial Pharmaceuticals, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will AZR stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +58.4% from the last close, and Ticker Nerd's factor model ranks Adial Pharmaceuticals, Inc. 21 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AZR stock forecast for 2030?

No analyst covering Adial Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AZR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $11 over the next 12 months.

How has AZR stock performed over the past year?

Adial Pharmaceuticals, Inc. returned -46.8% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Adial Pharmaceuticals, Inc. do?

Adial Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing prescription therapies for addiction and related disorders, with a current emphasis on alcohol use disorder.

What is the latest news on AZR?

The most recent item we track (GlobeNewsWire, 28 Oct 2026): "Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis". Adial Pharmaceuticals announced it has changed its corporate name to Azora Therapeutics, with its common stock expected to begin trading on Nasdaq under AZR on October 29, 2026. The company also announced a new executive team and said it expects to initiate a Phase 1 trial of AT177 in the first half of 2027.

Company

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing prescription therapies for addiction and related disorders, with a current emphasis on alcohol use disorder. Its lead program, AD04, is a genetically targeted serotonin-3 receptor antagonist being developed to help reduce heavy drinking in patients with specific biomarker profiles. The company also works on additional drug candidates aimed at non-opioid pain reduction and other medical conditions. Adial Pharmaceuticals, Inc. operates as a clinical-stage developer, concentrating on translating research into regulated therapeutic products through clinical studies and product development. The company’s current pipeline reflects a precision-medicine approach that seeks to match treatments with defined patient groups, placing it within the specialized segment of neuroscience and addiction-focused biopharmaceuticals.

CEO Mr. Cary John Claiborne MBA · 5 employees · United States · https://www.adial.com